Myriad Genetics, Inc. (MYGN)
| Market Cap | 542.92M -10.9% |
| Revenue (ttm) | 803.60M -2.6% |
| Net Income | -129.10M |
| EPS | -1.37 |
| Shares Out | 95.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,051,779 |
| Open | 5.71 |
| Previous Close | 5.68 |
| Day's Range | 5.51 - 5.71 |
| 52-Week Range | 2.74 - 8.09 |
| Beta | 1.61 |
| Analysts | Hold |
| Price Target | 5.90 (+4.24%) |
| Earnings Date | Nov 4, 2026 |
About MYGN
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic, a... [Read more]
Financial Performance
In 2025, Myriad Genetics's revenue was $824.50 million, a decrease of -1.56% compared to the previous year's $837.60 million. Losses were -$365.90 million, 187.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for MYGN stock is "Hold." The 12-month stock price target is $5.9, which is an increase of 4.24% from the latest price.
News
Myriad Genetics price target raised to $6 from $3 at Stephens
Stephens raised the firm’s price target on Myriad Genetics (MYGN) to $6 from $3 and keeps an Equal Weight rating on the shares. While the firm expects debates to remain…
Myriad Genetics Transcript: UBS Global Healthcare Conference
Q2 weakness reflected prenatal softness and hereditary cancer reimbursement pressure; guidance assumes these headwinds persist. Investments in payer operations, portfolio optimization and cancer-focused products target stronger growth, with initial Ascend benefits expected in 2027.
Myriad Genetics price target raised to $6.75 from $4.50 at TD Cowen
TD Cowen raised the firm’s price target on Myriad Genetics (MYGN) to $6.75 from $4.50 and keeps a Hold rating on the shares. Teh firm said their revenue beat was…
Myriad Genetics narrows FY26 revenue view to $780M-$790M from $770M-$790M
Consensus $777.92M. The company said, “Gross margins expected to fluctuate quarter to quarter given product mix and pricing trends.”
Myriad Genetics reports Q3 EPS (11c), consensus (20c)
Reports Q3 revenue $137.7M, consensus $191.33M. “We have made meaningful progress on our path to accelerate profitable growth and strengthen the company’s financial profile. Our third quarter 2026 fin...
Myriad Genetics Earnings Call Transcript: Q3 2026
Q3 revenue was $202.7M, with sequential gains in average revenue per test and improved adjusted EBITDA, while prenatal declines continued. The planned $210M-plus-inventory prenatal sale sharpens focus on cancer and mental health; FY2026 revenue midpoint rose to $785M.
Myriad Genetics Earnings release: Q3 2026
Myriad Genetics released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Myriad Genetics Slides: Q3 2026
Myriad Genetics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
Myriad Genetics Quarterly report: Q3 2026
Myriad Genetics has published its Q3 2026 quarterly earnings report on November 4, 2026.
Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives
Highl ights Third quarter 2026 revenue was $202.7 million, representing a 6% sequential increase and a 1% decrease year-over-year. Higher Cancer Care Continuum (CCC) product mix and continued progress...
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
SALT LAKE CITY, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that Myriad management will par...
Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
SALT LAKE CITY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces new data from the ongoing MONS...
TD says Myriad Genetics prenatal divestiture proceeds ahead of expectations
After Myriad Genetics (MYGN) announced a deal to sell its Prenatal Health testing business to Labcorp (LH) for $210M in cash plus closing inventory, TD Cowen analyst Kyle Boucher said…
Myriad Genetics upgraded to Neutral from Underweight at Piper Sandler
Piper Sandler upgraded Myriad Genetics (MYGN) to Neutral from Underweight with a price target of $5, up from $2, after the company announced a deal to sell its Prenatal Health…
Myriad Genetics to sell Prenatal Health testing business to Labcorp
Myriad Genetics (MYGN) announced a definitive agreement for Myriad to sell its Prenatal Health testing business, which includes the Prequel, Foresight, SneakPeek, and FirstGene tests, to Labcorp (LH) ...
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
SALT LAKE CITY and BURLINGTON, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and Labcorp (NYSE: LH), a ...
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
SALT LAKE CITY, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2026 earnings conf...
Myriad Genetics price target raised to $4.50 from $4 at TD Cowen
TD Cowen raised the firm’s price target on Myriad Genetics (MYGN) to $4.50 from $4 and keeps a Hold rating on the shares. The firm adjusted targets in the diagnostics…
Myriad, Sophia advance prostate cancer-specific genomic instability score tech
Myriad Genetics (MYGN) and Sophia Genetics (SOPH) announced a collaboration to advance new prostate cancer-specific genomic instability score technology to support precision oncology approaches with A...
Sophia Genetics and Myriad Genetics collaborate in prostate cancer score tech
Sophia Genetics (SOPH) and Myriad Genetics (MYGN) announced a collaboration to advance new prostate cancer-specific genomic instability score technology – or PrGIS – to support precision oncology appr...
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) t...
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability...
Myriad Genetics price target raised to $8 from $4 at Craig-Hallum
Craig-Hallum raised the firm’s price target on Myriad Genetics (MYGN) to $8 from $4 and keeps a Buy rating on the shares. The firm believes that shares could double or…
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been p...
Myriad Genetics Transcript: Wells Fargo 21st Annual Healthcare Conference
Q2 saw revenue and ASP declines due to prenatal and hereditary cancer reimbursement pressures, leading to conservative guidance. Strategic initiatives like Project Ascend and a portfolio review focus on cancer care, while new products and operational improvements aim to drive future growth.